What If You Could Stop a Global Killer with Just Your Smartphone?

April 22, 2025

logo

Disseminated on behalf of Light AI Inc. Please Read Disclosures

(OHCFF.USOTC)

Dear Reader,

If someone asked you to name the deadliest threats to children today, your mind might go to war, hunger, or maybe even climate disasters. But I’m willing to bet this name wouldn’t make your list:

Strep A.

It doesn’t sound like much. It’s a common bacteria—one you’ve probably had at some point without even realizing. But here’s the shocking truth:

Strep A kills more children every year than malaria.

And it infects over 600 million people annually, spreading across both developed and developing countries with brutal efficiency. [i]

The medical community has known about the threat for years. But while the world focused its attention on flashier problems, Strep A has quietly grown into a global catastrophe—one that’s about to strain our healthcare systems to the breaking point.

And that’s only the beginning.

The rise of drug-resistant bacteria—superbugs—is pushing us toward a world where basic infections become untreatable. The World Bank warns that by 2050, antimicrobial resistance could slash 3.8% off global GDP annually, shove 28 million people into poverty, and add $159 billion to annual healthcare costs. [ii][iii]

This isn’t just a health issue. It’s a looming economic disaster.

But what if I told you that one company may have cracked the code on how to stop this runaway train?

And they did it with nothing more than a smartphone and AI.

The 45-Second Revolution

Meet Light AI Inc. (OHCFF.USOTC).

Their mission is as bold as it is urgent: transform how we detect infections—starting with Strep A—by making testing radically faster, simpler, and more accurate.

How? Their patented technology uses your smartphone’s camera, backed by a powerful AI engine, to scan and analyze a patient’s throat in just 45 seconds. No lab work. No swabs. No delay. Just a rapid diagnosis, right on the spot.

In early clinical studies, Light AI’s platform has already achieved 96.57% accuracy—a figure that outperforms many traditional diagnostic tools. [i]

To put that into perspective, consider this: the current process of diagnosing Strep A involves doctor visits, referrals, lab swabs, and a waiting period that can stretch to 72 hours or more. Meanwhile, infected patients go untreated—or worse, receive unnecessary antibiotics, fueling the rise of superbugs.

Did you know that for every 10 sore throat visits, doctors prescribe antibiotics six times—but only two or three actually need them? [i] That’s a misdiagnosis rate that’s not just inefficient—it’s dangerous.

In 2019 alone, drug-resistant infections killed 5 million people worldwide. [iii] And the overprescription of antibiotics is a major contributor to that crisis.

The Stakes Are Too High to Ignore

The problem isn’t just the bacteria—it’s the system.

Healthcare costs are spiraling out of control. Between 2019 and 2022, labor costs in healthcare rose 37%. Today, administrative overhead eats up 25% of America’s staggering $4.3 trillion annual healthcare spend. [v]

These are numbers that make you sit up and take notice.

Hospitals are understaffed. Labs are overloaded. Patients wait days for answers. But Light AI’s technology could bypass all of that—with a tool nearly every person on the planet already owns: a smartphone.

And here’s where it gets interesting: this isn’t some future fantasy. Light AI has already built a proprietary database of over 300,000 clinical images, training their AI to recognize infection patterns with surgical precision. In fact, they’ve improved their system from 56% to 96.57% accuracy in just a few years. [i]

What took physicians a lifetime to master, this AI can now outperform in seconds.

Even Stanford University researchers are seeing the potential. A recent study revealed that AI tools can diagnose medical conditions with 92% accuracy, compared to 74% for traditional physicians. [vii]

Why This Matters to You Now

Let’s be honest—investing in early-stage companies always carries risk. But every once in a while, a new idea, a new category, a new technology emerges that makes the risk feel worthwhile.

This could be one of those moments.

Light AI isn’t just creating a new product. They’re pioneering a new category in diagnostics: one where disease detection becomes mobile, immediate, and accessible anywhere—from a clinic in New York to a village in Nairobi.

With global health threats mounting and infrastructure crumbling under pressure, the world desperately needs solutions like this.

And investors who recognize that need early on are often the ones who benefit most.

In our next alert, I’ll show you how Light AI is poised to dominate three different healthcare markets at once—including one that doesn’t even require FDA approval.

For now, take a good hard look at Light AI (OHCFF.USOTC).

This could be the start of something very big.

Kiyosaki Research

References

i LightAI Investor Presentation

ii "Superbugs could jeopardise food security for over two billion people", WOAH

iii "Antimicrobial Resistance (AMR)", World Bank

iv "AI in Healthcare Market Size, Share & Industry Analysis", Fortune Business Insights

v "The Potential Financial Benefits of AI in Healthcare Organizations", InfoTech

vi "Ten threats to global health in 2019", World Health Organization

vii "AI Medical Tools Show Promise as Health Tech Markets Rally", PYMNTS

viii "Artificial Intelligence in Diagnostics Market Size to Hit USD 8.54 Bn by 2033", BioSpace

ix “Category Design for Entrepreneurs: How to Become a Category King”, Category Pirates

x "AI in Diagnostics Market Size Skyrockets by 24.64% CAGR by 2034", Globe Newswire

xi "Artificial intelligence could save healthcare industry $360B a year", Healthcare Dive

xii "HealthTech Startups Valuation: Methods, Challenges and AI Adoption", Finrofca

xiii "2024 shaping up to be a big year for healthcare AI companies", Fierce Healthcare

xiv "A.I. Chatbots Defeated Doctors at Diagnosing Illness", New York Times

xv “New AAMC Report Shows Continuing Projected Physician Shortage”, AAMC

xvi "Artificial Intelligence in Medical Diagnostics Market to Hit USD 4.72 Billion by 2029", Yahoo Finance

IMPORTANT DISCLAIMER & DISCLOSURES

Investing in stocks is HIGH RISK. You could lose all of your investment.

Freedom Financial Research, as a publisher, is not a broker, investment advisor, or financial advisor in any jurisdiction.

Please do not rely on the information presented by Freedom Financial Research as personal investment advice.

If you need personal investment advice, kindly reach out to a qualified and registered broker, investment advisor, or financial advisor.

The communications from Freedom Financial Research should not form the basis of your investment decisions. Examples we provide regarding share price increases related to specific companies are based on randomly selected time periods and should not be taken as an indicator or predictor of future stock prices for those companies.

Light AI Inc. is a paid sponsor of this report.

The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom.

Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Freedom Financial Research nor any employee of Freedom Financial Research is not registered with the United States Securities and Exchange Commission (the “SEC”): as a “broker-dealer” under the Exchange Act, as an “investment adviser” under the Investment Advisers Act of 1940, or in any other capacity. Freedom Financial Research, its owners, directors, and employees are also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.

DISCLAIMER: Freedom Financial Research, LLC (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Light AI Inc. made a one-time payment of fifty-five thousand USD to provide marketing services for a term of one week This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing ,including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR+ and SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

Freedom Financial Research and its directors, employees, and members of their households do not own any shares of Light AI Inc. (OHCFF:USOTC). However, Freedom Financial Research is extremely biased since this is a sponsored editorial.

HIGH RISK: The securities issued by the companies we feature should be seen as high risk; if you choose to invest, despite these warnings, you may lose your entire investment. You must be aware of the risks and be willing to accept them in order to invest in financial instruments, including stocks, options, and futures.

NOT PROFESSIONAL ADVICE: By reading this, you agree to all of the following: You understand this to be an expression of opinions and NOT professional advice. You are solely responsible for the use of any content and hold Freedom Financial Research and all partners, members, and affiliates harmless in any event or claim. While Freedom Financial Research strives to provide accurate and reliable information sourced from believed-to-be trustworthy sources, we cannot guarantee the accuracy or reliability of the information. The information provided reflects conditions as they are at the moment of writing and not at any future date. Freedom Financial Research is not obligated to update, correct, or revise the information post-publication.

FORWARD-LOOKING STATEMENTS: This article contains forward-looking statements about Light AI Inc., which are identified by terms such as "anticipate," "expect," and "project." These statements reflect current views regarding company performance, business goals, healthcare market expectations, and intellectual property development. The statements are based on current business and market expectations. However, they involve various risks and uncertainties, including potential delays, financial difficulties, operational challenges, and problems protecting intellectual property. Additional risks include possible regulatory approval delays, market disruptions, personnel issues, and competitive pressures. Given these risks and uncertainties, actual results may differ significantly from what is described in the forward-looking statements. Readers should not place undue reliance on these statements, which are only valid as of the article's publication date and we undertake no obligation to update.